TY  - GEN
AU  - Montero, Maria M
AU  - Domene-Ochoa, Sandra
AU  - López-Causapè, Carla
AU  - VanScoy, Brian
AU  - Luque, Sonia
AU  - Sorli, Luisa
AU  - Campillo, Nuria
AU  - Padilla, Eduardo
AU  - Prim, Nuria
AU  - Segura, Concepcion
AU  - Pomar, Virginia
AU  - Rivera, Alba
AU  - Grau, Santiago
AU  - Ambrose, Paul G
AU  - Oliver, Antonio
AU  - Horcajada, Juan P
PY  - 2019
DO  - 10.1016/j.jgar.2019.04.012
SN  - 2213-7165
UR  - https://hdl.handle.net/20.500.12105/22700
AB  - Background: Extensively drug-resistant (XDR) Pseudomonas aeruginosa (P. aeruginosa) and particularly P. aeruginosa high-risk clones, are of growing concern because treatment options are limited. For years, colistin monotherapy has been the only...
LA  - eng
PB  - Elsevier
KW  - Colistin
KW  - Meropenem
KW  - Combination therapy
KW  - Pseudomonas aeruginosa
KW  - Synergy
KW  - Meropenem
KW  - Colistin
KW  - Drug Resistance, Multiple, Bacterial
KW  - Spain
KW  - Anti-Bacterial Agents
KW  - Microbial Sensitivity Tests
KW  - Drug Synergism
KW  - Humans
KW  - Drug Therapy, Combination
KW  - Pseudomonas aeruginosa
KW  - Pseudomonas Infections
TI  - Colistin plus meropenem combination is synergistic in vitro against extensively drug-resistant Pseudomonas aeruginosa, including high-risk clones
TY  - research article
ER  -